Ng Charlotte K Y, Piscuoglio Salvatore, Geyer Felipe C, Burke Kathleen A, Pareja Fresia, Eberle Carey A, Lim Raymond S, Natrajan Rachael, Riaz Nadeem, Mariani Odette, Norton Larry, Vincent-Salomon Anne, Wen Y Hannah, Weigelt Britta, Reis-Filho Jorge S
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Institute of Pathology, University Hospital Basel, Basel, Switzerland.
Clin Cancer Res. 2017 Jul 15;23(14):3859-3870. doi: 10.1158/1078-0432.CCR-16-2857. Epub 2017 Feb 2.
Metaplastic breast carcinoma (MBC) is a rare and aggressive histologic type of breast cancer, predominantly of triple-negative phenotype, and characterized by the presence of malignant cells showing squamous and/or mesenchymal differentiation. We sought to define the repertoire of somatic genetic alterations and the mutational signatures of MBCs. Whole-exome sequencing was performed in 35 MBCs, with 16, 10, and 9 classified as harboring chondroid, spindle, and squamous metaplasia as the predominant metaplastic component. The genomic landscape of MBCs was compared with that of triple-negative invasive ductal carcinomas of no special type (IDC-NST) from The Cancer Genome Atlas. Wnt and PI3K/AKT/mTOR pathway activity was assessed using a qPCR assay. MBCs harbored complex genomes with frequent (69%) mutations. In contrast to triple-negative IDC-NSTs, MBCs more frequently harbored mutations in (29%), (11%), (11%), (11%), and (11%). mutations were not found in MBCs with chondroid metaplasia. Compared with triple-negative IDC-NSTs, MBCs significantly more frequently harbored mutations in PI3K/AKT/mTOR pathway-related (57% vs. 22%) and canonical Wnt pathway-related (51% vs. 28%) genes. MBCs with somatic mutations in PI3K/AKT/mTOR or Wnt pathway-related genes displayed increased activity of the respective pathway. MBCs are genetically complex and heterogeneous, and are driven by a repertoire of somatic mutations distinct from that of triple-negative IDC-NSTs. Our study highlights the genetic basis and the importance of PI3K/AKT/mTOR and Wnt pathway dysregulation in MBCs and provides a rationale for the metaplastic phenotype and the reported responses to PI3K/AKT/mTOR inhibitors in these tumors. .
化生性乳腺癌(MBC)是一种罕见且侵袭性强的组织学类型乳腺癌,主要为三阴性表型,其特征是存在显示鳞状和/或间充质分化的恶性细胞。我们试图确定MBC的体细胞基因改变谱和突变特征。对35例MBC进行了全外显子测序,其中16例、10例和9例分别以软骨样、梭形和鳞状化生为主要化生成分。将MBC的基因组图谱与来自癌症基因组图谱的三阴性非特殊类型浸润性导管癌(IDC-NST)的图谱进行比较。使用qPCR检测评估Wnt和PI3K/AKT/mTOR信号通路活性。MBC具有复杂的基因组,频繁发生(69%)突变。与三阴性IDC-NST相比,MBC更频繁地发生(29%)、(11%)、(11%)、(11%)和(11%)的突变。在具有软骨样化生的MBC中未发现突变。与三阴性IDC-NST相比,MBC在PI3K/AKT/mTOR信号通路相关基因(57%对22%)和经典Wnt信号通路相关基因(51%对28%)中发生突变的频率显著更高。在PI3K/AKT/mTOR或Wnt信号通路相关基因中发生体细胞突变的MBC显示出相应信号通路活性增加。MBC在基因上是复杂且异质的,由一系列不同于三阴性IDC-NST的体细胞突变驱动。我们的研究突出了MBC中PI3K/AKT/mTOR和Wnt信号通路失调的遗传基础及重要性,并为这些肿瘤的化生表型和报道的对PI3K/AKT/mTOR抑制剂的反应提供了理论依据。